Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
AstraZeneca Pharmaceuticals LP

2. Address

Address1
1800 CONCORD PIKE, P.O. BOX 15437
 Address2
​
City
WILMINGTON
 State
DE
 Zip Code
19850-5437
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Ms.
​Sarah Arbes
​2022467003
​sarah.arbes@astrazeneca.com
5. Senate ID#
​54073-12
7. Client Name Self Check if client is a state or local government or instrumentality
​AstraZeneca Pharmaceuticals LP
6. House ID#
​349750000
TYPE OF REPORT 8. Year
​2023
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​950,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Sarah Arbes
 Date
10/20/2023 5:19:51 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

-Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language), Medicare negotiation and Medicare Part D reform and redesign and inflation penalties.
-Issues related to the orphan drug exclusion of the Inflation Reduction Act.
-Issues related to reauthorization of the Pandemics and All-Hazards Preparedness Act (PAHPRA).
General issues related to rare disease and orphan drugs.
-General issues related to health equity in rare disease and clinical trials.
-General issues related to diagnostics for patients with rare diseases.
-PBM reform
-FDA modernization policy issues
-FDA reform initiatives
-Reauthorization of newborn screening programs.
-H.R. 5539 ORPHAN Cures Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Elizabeth
Brooks
​
​
Katie
Jones
​
​
Sarah
Arbes
​
​
Helen
Dwight
​
​
Caroline
Quat
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

-Issues related to implementation of the Inflation Reduction Act of 2022 (Public Law No. 117-169).
-Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub. L. 117-169.
-Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies.
-Issues related to the Medicaid Drug Rebate Program
-CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure.
-Centers for Medicare and Medicaid Innovation (CMMI) policy issues.
-Medicare patient access to rare disease therapies, Part B and Part D drugs.
-Medicaid (Medicaid Drug Rebate Program) stacking issues.
-Value-based payment arrangements.
-Efforts to improve coding, coverage, and access for rare disease therapies.
-General issues related to diagnostic reimbursement.
-S. 2085, the Medicare Multi-Cancer Early Detection Screening Coverage Act
-H.R. 3876 Access to Genetic Counselor Services Act of 2023.
-HR 5539, Orphan Cures Act (expanding orphan drug exclusion in IRA)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Helen
Dwight
​
​
Elizabeth
Brooks
​
​
Katie
Jones
​
​
Sarah
Arbes
​
​
Caroline
Quat
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

-Issues related to Pharmacy Benefit Managers (PBMs).
-Issues related to pharmacy benefit management (PBM) reform
-Issues related to implementation of the Inflation Reduction Act of 2022 (Public Law No. 117-169).
-General advocacy on PBMs, IRA, inhalers
-Issues related to the orphan drug exclusion of the Inflation Reduction Act.
-Issues related to 340B reform.
-Issues related to the 340B Drug Pricing Program

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Helen
Dwight
​
​
Elizabeth
Brooks
​
​
Katie
Jones
​
​
Sarah
Arbes
​
​
Caroline
Quat
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

-Issues related to the Orphan Drug Tax Credit.
-Issues related to the deduction of research and development expenditures.
-H.R. 1350, Camerons Law.
-H.R.2673, American Innovation and R&D Competitiveness Act of 2023.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Helen
Dwight
​
​
Elizabeth
Brooks
​
​
Katie
Jones
​
​
Sarah
Arbes
​
​
Caroline
Quat
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to pharmaceutical patents

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Helen
Dwight
​
​
Elizabeth
Brooks
​
​
Katie
Jones
​
​
Sarah
Arbes
​
​
Caroline
Quat
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​Aaron
​Hunter
​
3
​
​
​
2
​Helen
​Dwight
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)